In a startling turn of events, the Food and Drug Administration (FDA) issued a warning to MedisourceRx, a pharmacy that specializes in compounding medications and is part of the Hims & Hers family, following troubling discoveries made during an inspection. This warning came about six months after the facility was flagged for various concerning issues.
One major point of contention was the pharmacy's failure to report a significant adverse event involving a patient who suffered serious side effects after using a compounded version of semaglutide, the active ingredient in the well-known weight-loss drug, Wegovy, manufactured by Novo Nordisk. According to an official FDA inspection report from May and June of last year, this incident took place in January 2025. A patient experienced intense stomach problems and ended up hospitalized for three nights after receiving the compounded injectable medication. Alarmingly, MedisourceRx, which became part of Hims & Hers in September 2024, did not notify the FDA within the mandated 15-day window after learning about the issue, as required by federal regulations.
This situation raises critical questions about the safety protocols and oversight at compounding pharmacies. How could such a serious incident go unreported for so long? The implications of this oversight are vast, potentially affecting not just the company’s reputation, but also the trust patients place in compounded medications. What do you think about the responsibilities of pharmacies in reporting adverse events? Join the discussion and share your thoughts!
